Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Durvalumab + MEDI0457 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 100 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov). |
MEDI0457 | INO-3112|INO3112|INO 3112|MEDI 0457|MEDI-0457 | MEDI0457 (INO-3112) is an immunotherapy consisting of DNA plasmids encoding HPV oncoproteins, E6 and E7, along with interleukin-12 (IL-12) (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5525-5525, PMID: 32151670). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04001413 | Phase II | Durvalumab Durvalumab + MEDI0457 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Withdrawn | USA | 0 |
NCT03439085 | Phase II | Durvalumab + MEDI0457 | Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers | Active, not recruiting | USA | 0 |
NCT03162224 | Phase Ib/II | Durvalumab + MEDI0457 | Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer | Completed | USA | 0 |